Surmodics (SRDX) Stock Price
Surmodics Price
Over the last 19 years Surmodics grew revenue by 3.8% annually, reaching 126.08 M USD. Earnings per share have declined at 8.2% per year over the last 15 years. For Surmodics, the net margin of -9.2% is down versus 1.2% a few years ago. The consensus 12-month price target for Surmodics is 43.86 USD, about 2.0% above where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 63% above its 52-week low.
Surmodics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Surmodics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Surmodics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Surmodics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Surmodics Price |
|---|---|
| 11/27/2025 | 42.98 USD |
| 11/25/2025 | 42.98 USD |
| 11/24/2025 | 42.98 USD |
| 11/23/2025 | 42.98 USD |
| 11/20/2025 | 42.98 USD |
| 11/19/2025 | 42.98 USD |
| 11/18/2025 | 42.98 USD |
| 11/17/2025 | 42.83 USD |
| 11/14/2025 | 41.61 USD |
| 11/13/2025 | 41.41 USD |
| 11/12/2025 | 41.35 USD |
| 11/11/2025 | 40.94 USD |
| 11/10/2025 | 27.35 USD |
| 11/7/2025 | 26.79 USD |
| 11/6/2025 | 26.42 USD |
| 11/5/2025 | 27.55 USD |
| 11/4/2025 | 27.50 USD |
| 11/3/2025 | 28.32 USD |
| 10/31/2025 | 27.44 USD |
| 10/30/2025 | 27.17 USD |
| 10/29/2025 | 26.93 USD |
| 10/28/2025 | 27.36 USD |
| 10/27/2025 | 27.46 USD |
| 10/23/2025 | 27.50 USD |
| 10/22/2025 | 28.28 USD |
| 10/21/2025 | 28.10 USD |
| 10/20/2025 | 28.13 USD |
| 10/16/2025 | 28.00 USD |
| 10/15/2025 | 27.72 USD |
| 10/14/2025 | 27.59 USD |
Surmodics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.00 | 56.00 | 57.00 | 61.00 | 71.00 | 73.00 | 81.00 | 100.00 | 94.00 | 105.00 | 99.00 | 132.00 | 126.00 | 117.00 | 123.00 | 129.00 |
| -23.88 | 9.80 | 1.79 | 7.02 | 16.39 | 2.82 | 10.96 | 23.46 | -6.00 | 11.70 | -5.71 | 33.33 | -4.55 | -7.14 | 5.13 | 4.88 |
| 86.27 | 58.93 | 57.89 | 60.66 | 57.75 | 39.73 | 32.10 | 33.00 | 30.85 | 39.05 | 29.29 | 46.21 | 73.81 | 73.81 | 73.81 | 73.81 |
| 44.00 | 33.00 | 33.00 | 37.00 | 41.00 | 29.00 | 26.00 | 33.00 | 29.00 | 41.00 | 29.00 | 61.00 | 93.00 | 86.36 | 90.79 | 95.21 |
| 16.00 | 18.00 | 18.00 | 19.00 | 16.00 | 7.00 | -8.00 | 6.00 | -1.00 | 6.00 | -21.00 | 5.00 | -3.00 | -3.00 | -3.00 | -4.00 |
| 31.37 | 32.14 | 31.58 | 31.15 | 22.54 | 9.59 | -9.88 | 6.00 | -1.06 | 5.71 | -21.21 | 3.79 | -2.38 | -2.56 | -2.44 | -3.10 |
| 10.00 | 15.00 | 12.00 | 13.00 | 9.00 | 3.00 | -4.00 | 7.00 | 1.00 | 4.00 | -27.00 | -1.00 | -11.00 | -4.00 | -1.00 | 4.00 |
| -183.33 | 50.00 | -20.00 | 8.33 | -30.77 | -66.67 | -233.33 | -275.00 | -85.71 | 300.00 | -775.00 | -96.30 | 1,000.00 | -63.64 | -75.00 | -500.00 |
| 14.86 | 14.01 | 13.42 | 13.19 | 13.45 | 13.06 | 13.83 | 13.77 | 13.67 | 13.88 | 13.98 | 14.10 | 14.23 | 14.23 | 14.23 | 14.23 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Surmodics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Surmodics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Surmodics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Surmodics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Surmodics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Surmodics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics business model & stock analysis
Surmodics SWOT Analysis
Strengths
- Established brand with a good reputation in the healthcare industry.
- Diverse portfolio of innovative medical devices and diagnostic products.
- Strong intellectual property rights, providing a competitive advantage.
- Solid financial position and consistent revenue growth.
Weaknesses
- Reliance on a limited number of major customers, posing a potential risk.
- Vulnerability to changes in government regulations and reimbursement policies.
- Limited global presence compared to some competitors.
- Potential product recalls or legal issues may impact reputation and financials.
Opportunities
- Growing demand for minimally invasive medical procedures, offering market expansion prospects.
- Increasing focus on personalized medicine and companion diagnostics.
- Potential partnerships and collaborations to enhance product offerings and market reach.
- Continuous advancements in medical technology present opportunities for product innovation.
Threats
- Intense competition from larger and more established companies.
- Economic downturns affecting healthcare spending and customer budget constraints.
- Rapidly evolving regulatory landscape impacting product development and market access.
- Potential disruptions in supply chain and manufacturing processes.
Surmodics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Segments
Surmodics Revenue by Segment (1/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
Surmodics Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
Surmodics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Surmodics historical P/E ratio, EBIT multiple, and P/S ratio
Surmodics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Surmodics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Surmodics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Surmodics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Surmodics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Surmodics stock splits
Since 2000, a total of 2 shares have been converted from one Surmodics share.
Current Surmodics forecasts and price targets in September 2026
Analyst Price Targets 2026Surmodics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 11/14/2025 | Downgrade | Market PerformUnderperform | 70 | |
| 8/11/2025 | Maintained | Market Perform | 70 | |
| 4/30/2025 | Maintained | Hold | 58 | |
| 3/7/2025 | Upgrade | HoldBuy | – | |
| 1/30/2025 | Maintained | Hold | 58 | |
| 5/30/2024 | Downgrade | OutperformMarket Perform | 70 | |
| 5/29/2024 | Downgrade | BuyNeutral | 81 | |
| 5/29/2024 | Downgrade | BuyHold | 58 | |
| 5/29/2024 | Downgrade | BuyHold | – | |
| 5/2/2024 | Maintained | Outperform | 70 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Surmodics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/6/2026 | -0.03USD | - | 31.65 MUSD | - | 2026 Q3 |
| 4/28/2026 | -0.03USD | - | 31.06 MUSD | - | 2026 Q2 |
| 1/28/2026 | -0.13USD | - | 30.61 MUSD | - | 2026 Q1 |
| 8/8/2025 | -0.21USD | 0.06USD | 28.06 MUSD | - | 2025 Q2 |
| 4/30/2025 | -0.11USD | -0.13USD | 32.23 MUSD | - | 2025 Q1 |
| 1/30/2025 | -0.12USD | -0.04USD | 33.37 MUSD | - | 2024 Q4 |
| 11/5/2024 | -0.27USD | -0.13USD | 30.40 MUSD | - | 2024 Q3 |
| 7/31/2024 | -0.31USD | -0.27USD | 29.95 MUSD | - | 2024 Q2 |
| 5/1/2024 | -0.36USD | 0.07USD | 28.84 MUSD | - | 2024 Q1 |
| 1/31/2024 | -0.30USD | -0.06USD | 29.64 MUSD | - | 2023 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Surmodics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Surmodics shareholder structure
| % | Name |
|---|---|
7.13280% | |
5.94735% | |
5.66563% | |
5.51790% | |
5.21556% | |
5.01247% |
Surmodics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
16.30% | SEC ↗ | |
16.20% | SEC ↗ | |
12.00% | SEC ↗ | |
12.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
10.62% | SEC ↗ | |
10.62% | SEC ↗ | |
8.95% | SEC ↗ | |
8.95% | SEC ↗ |
Surmodics Executives and Management Board
10 members · avg. age 63 · 30 % women
Mr. Gary Maharaj (61)
President, Chief Executive Officer, Director · since 2010
3.67 M USD
Management
Ms. Teryl Sides (55)
Senior Vice President, President - Vascular Interventions
Mr. Timothy Arens (57)
Chief Financial Officer, Senior Vice President - Finance and Information Technology
Mr. Gordon Weber (61)
Senior Vice President - Legal, General Counsel, Secretary
Mr. Charles Olson (60)
Senior Vice President, President - Medical Device Coatings
Mr. Joseph Stich (59)
Senior Vice President of Human Resources, President - In Vitro Diagnostics
Board of Directors
Ms. Susan Knight (70)
Non-Executive Independent Chairman of the Board
Dr. David Dantzker (81)
Independent Director
Ms. Lisa Heine (61)
Independent Director
Mr. Jose Bedoya (68)
Independent Director
Surmodics Supply Chain
Surmodics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.26 | 0.90 | 0.78 | ||
| 2 | 0.50 | 0.50 | 0.50 | ||
| 3 | 0.84 | 0.19 | 0.41 | ||
| 4 | 0.89 | 0.95 | 0.40 | ||
| 5 | 0.59 | 0.74 | 0.37 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Qualigen Therapeutics | 0.75 | 0.77 | -0.21 | |
| 2 | 0.18 | -0.16 | 0.16 | ||
| 3 | -0.40 | -0.27 | 0.21 |
Frequently asked questions about Surmodics
Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.
Surmodics Inc is primarily active in the healthcare and medical device industry.
The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.
Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.
Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.
Surmodics Inc is primarily present in the United States.
Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.
Analysts currently set an average price target of 43.86 USD for the Surmodics stock (median: 43.86 USD), implying +2.0 % versus the latest price. The consensus is based on 9 analyst ratings.
7 analysts currently rate the Surmodics stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Surmodics to generate revenue of 123.01 M USD and earnings per share of -0.12 USD.
Converted at the current exchange rate, the Surmodics share trades at 37.70 EUR (42.98 USD).
The Surmodics share (SRDX) is listed on 2 stock exchanges, including: NASDAQ (SRDX), Frankfurt (SU6.F).
Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.
The expected revenue of Surmodics is 123.01 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Surmodics is -1.72 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Surmodics is currently -356.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Surmodics stock.
The price-to-sales ratio (P/S) of Surmodics is currently 4.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Surmodics stock.
The Eulerpool Quality Score for Surmodics is 2/10.
The ISIN of Surmodics is US8688731004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Surmodics is 914178. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Surmodics is SRDX. The ticker symbol is used to trade Surmodics shares on the stock exchange.
Surmodics paid dividends every year for the past 0 years.
Surmodics is assigned to the 'Health' sector.
The dividends of Surmodics are distributed in USD.
Surmodics stock
Surmodics Peer Group
Surmodics Ticker
Surmodics FIGI
All fundamentals and in-depth analysis of Surmodics
Our stock analysis for Surmodics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surmodics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.